(Q44198605)

30 November 2017

Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin (English)

1 reference

polycystic ovary syndrome

30 November 2017

1 reference

1 reference

1 reference

1 reference

Charles J Glueck

1

1 reference

30 November 2017

Ping Wang

series ordinal

2

1 reference

30 November 2017

Naila Goldenberg

series ordinal

3

1 reference

30 November 2017

Luann Sieve-Smith

series ordinal

4

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

30 November 2017

1 reference

30 November 2017

17

1 reference

30 November 2017

2858-2864

1 reference

30 November 2017

11

1 reference

Metformin in management of pregnant insulin-independent diabetics

30 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Clinical assessment of body hair growth in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Genetic hypofibrinolysis in complicated pregnancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

A prospective analysis of the HOMA model. The Mexico City Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Oral hypoglycaemic agents in 118 diabetic pregnancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Effects of metformin on early pregnancy loss in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F17.11.2858

10.1093/HUMREP/17.11.2858

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference